Shandong Qilu Stem Cells Engineering Co., Ltd.
7
2
2
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Clinical Study on the Safety and Efficacy of Umbilical Cord Blood Infusion in Treating Bone Marrow Suppression .
Role: lead
Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases
Role: lead
Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders
Role: lead
Human Cord Blood Mononuclear Cells in the Treatment of Refractory Diabetic Foot
Role: collaborator
Clinical Study of Umbilical Cord Blood Mononuclear Cells (UCB-MNCs) in the Treatment of Traumatic Fracture Healing
Role: collaborator
Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis
Role: lead
Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis
Role: lead
All 7 trials loaded